Black Diamond Therapeutics (BDTX) Cash & Equivalents (2018 - 2026)

Black Diamond Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $30.1 million for Q1 2026.

• Quarterly Cash & Equivalents fell 69.45% year-over-year to $30.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.1 million (down 69.45% YoY) and the FY2025 annual result came in at $21.0 million, down 42.39% from the prior year.
• Cash & Equivalents was $30.1 million for Q1 2026 at Black Diamond Therapeutics, up from $21.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $98.4 million in Q1 2025 and bottomed at $21.0 million in Q4 2025.
• A 5-year average of $42.5 million and a median of $36.4 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents soared 287.16% — and 2026, when it plunged 69.45%.
• Black Diamond Therapeutics' Cash & Equivalents stood at $34.3 million in 2022, then jumped by 63.84% to $56.2 million in 2023, then slumped by 35.19% to $36.4 million in 2024, then sank by 42.39% to $21.0 million in 2025, then jumped by 43.26% to $30.1 million in 2026.
• Business Quant data shows BDTX's Cash & Equivalents at $30.1 million in Q1 2026, $21.0 million in Q4 2025, and $30.9 million in Q3 2025.